Zydus Lifesciences Global FZE, a subsidiary of Zydus, has entered into an agreement with Bioeq for the US commercialisation of Vascular Endothelial Growth Factor (VEGF) inhibitor Nufymco, an interchangeable biosimilar of Lucentis (Ranibizumab).
This move follows the US Food and Drug Administration’s (FDA) approval of the Biologics License Application for Nufymco, expanding Zydus’ biosimilar portfolio in the US.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Under the terms of the partnership, Bioeq will handle the development, manufacturing, registration along with supply of the finished product, while Zydus will focus on Nufymco’s commercialisation across the US market.
Zydus Lifesciences managing director Dr Sharvil Patel said: “We are happy to collaborate with Bioeq to bring an interchangeable biosimilar to Lucentis (Ranibizumab) in the US market.
“Through this partnership, we will leverage our combined expertise and resources to accelerate organisational growth while ensuring maximum value to patients through an expanded access to affordable ophthalmology care.”
Bioeq commercial vice-president Dr Thiemo Schreiber said: “We are excited about the regulatory approval of Nufymco by USFDA as an interchangeable biosimilar of Lucentis (Ranibizumab). This latest addition to our portfolio reflects Bioeq’s advanced expertise in developing complex biosimilar medicines for highly regulated markets.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Our partnership with Zydus will leverage its extensive distribution network and strong sales and marketing capabilities across the US to broaden treatment options for patients.
“We are committed to delivering high-quality, affordable therapies and look forward to this collaboration tailored to driving innovation and improving healthcare accessibility.”
Earlier this month, Zormycon and Zydus Lifesciences entered into an exclusive licensing and supply agreement for FYB206, a biosimilar of MSD’s Keytruda, in Canada and the US.
